Susquehanna International Group
PHAT icon

Susquehanna International Group’s Phathom Pharmaceuticals PHAT Stock Holding History

Susquehanna International Group’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$459K Buy
41,300
+22,400
+119% +$283K ﹤0.01% 9899
2025
Q4 		$314K Sell
18,900
-1,000
-5% -$14.3K ﹤0.01% 9838
2025
Q3 		$234K Sell
19,900
-384,700
-95% -$3.97M ﹤0.01% 10645
2025
Q2 		$3.88M Buy
404,600
+385,800
+2,052% +$2.13M ﹤0.01% 4456
2025
Q1 		$118K Sell
18,800
-238,600
-93% -$1.45M ﹤0.01% 11425
2024
Q4 		$2.09M Buy
257,400
+239,100
+1,307% +$2.96M ﹤0.01% 5222
2024
Q3 		$331K Sell
18,300
-11,900
-39% -$166K ﹤0.01% 9383
2024
Q2 		$311K Sell
30,200
-19,500
-39% -$201K ﹤0.01% 9360
2024
Q1 		$528K Buy
+49,700
New +$422K ﹤0.01% 8374
2023
Q4 		– Sell
-26,200
Closed -$272K – 13071
2023
Q3 		$272K Sell
26,200
-7,800
-23% -$107K ﹤0.01% 9571
2023
Q2 		$487K Buy
+34,000
New +$392K ﹤0.01% 8386
2021
Q1 		– Sell
-14,700
Closed -$488K – 12691
2020
Q4 		$488K Buy
+14,700
New +$596K ﹤0.01% 8345

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Susquehanna International Group's PHAT Position: Q1 2026 in Review

Susquehanna International Group reduced its Phathom Pharmaceuticals (PHAT) stake by 83% in Q1 2026, selling an estimated $5.76M and leaving 92,979 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #7809.

Susquehanna International Group first reported a position in PHAT in Q4 2020 and has held it in 15 quarters since. The position peaked at $9.11M in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Susquehanna International Group held 92,979 shares of Phathom Pharmaceuticals worth $1.03M as of Q1 2026.
  • Susquehanna International Group sold 456,192 Phathom Pharmaceuticals shares in Q1 2026, an estimated $5.76M.
  • Phathom Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7809 holding.
  • Susquehanna International Group first reported a position in Phathom Pharmaceuticals in Q4 2020 and has held it in 15 quarters since.
  • Susquehanna International Group's Phathom Pharmaceuticals position peaked at $9.11M in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.